Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galiximab and Rituximab in Untreated Follicular Lymphoma
NCT00117975Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2005
- Primary completion
- Jun 2007
- Countries
- 1
01
Overview
Phase 2, open-label trial of galiximab in follicular lymphoma (FL), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Response Rate at 12 months. Started Jun 2005; status: completed.
02
Drugs
galiximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00117975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117975.